
From early diagnosis to drug discovery, these femtech start-ups are on a mission to develop life-saving solutions to beat cancer and improve women’s lives.
Vara
Vara’s software platform aims to mitigate much of the human subjectivity associated with reading mammography results, reducing the repetitive work screening physicians are routinely subjected to.
The AI technology, developed by processing millions of mammograms, has been trained to identify patterns and help radiologists when reviewing mammograms. However, the more images it sees, the more accurate it gets.
Lattice Medical
The French biomedical start-up Lattice Medical is developing a disruptive bioabsorbable implant for breast reconstruction and breast augmentation.
The procedure uses autologous fat tissues injected into an absorbable implant allowing high volume reconstruction in one surgery.
This absorbable implant is based on fat tissue growing engineering material made of Calais laces and a 3D shell structure delimiting the reconstruction volume. Breasts are entirely reconstructed by the patient’s tissues and no foreign bodies are introduced.
AOA Dx
AOA Dx is a biotech company that focuses on early-stage ovarian cancer detection.
Co-founded by three experts and passionate women’s health advocates, the start-up is developing a “novel” approach to evaluate tumour marker gangliosides in liquid biopsies and develop new diagnostic tests.
AKRIVIS GD, its early-stage liquid biopsy test for ovarian cancer, has proven excellent sensitivity and specificity in a recent study.

Curiva
Curiva is a medical device company aiming to reduce the incidence of cervical cancer with a non-invasive diagnostic patch.
A microneedles mediated diagnostic patch, diaPatch, detects the early onset of cervical cancer, replacing invasive procedures such as the Pap smear and colposcopy.
According to developers, the patch will provide benefits to healthcare professionals for better management of guidelines and improved patient outcomes.
Teal Health
California-based Teal Health is developing the first FDA-approved at-home cervical cancer screening.
Currently, a cervical cancer screening is done in the doctor’s office by a clinician using stirrups and a speculum. By developing a novel self-collection device, the company aims to make it easier for women to collect samples from home.
Its platform aims to increase women’s confidence and adherence to screen for primary HPV and Pap cytology triage and enable conversation and engagement with medical professionals.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.










